Sayana® Press Approved for Self-Injection in the UK
The United Kingdom’s lead regulatory agency, the Medicines & Healthcare products Regulatory Agency (MHRA), has authorized self-injection of Pfizer’s subcutaneous injectable contraceptive, Sayana® Press, in that country. This update to the Sayana Press label adds the option for self-injection when considered appropriate by a health care professional, making it the first injectable contraceptive in the United Kingdom available for self-administration. Sayana Press is a lower-dose formulation and presentation of the three-month injectable contraceptive Depo-Provera®. Pfizer also announced plans to seek regulatory approval of the updated Sayana Press label in a number of additional countries with high unmet need and demand for injectable contraception, such as Burkina Faso, Uganda, and Senegal. You can read more in an announcement recently issued by PATH.